公开(公告)号：US09920047B2

公开(公告)日：2018-03-20

申请号：US15270863

申请日：2016-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81 ,  C07D285/08

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US09487509B2

公开(公告)日：2016-11-08

申请号：US14055585

申请日：2013-10-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shizuo Kasai ,  Tomohiro Kaku ,  Masahiro Kamaura

IPC: C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/22 ,  C07D211/44 ,  C07D211/46 ,  C07D211/78 ,  C07D211/88 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D413/06 ,  C07D413/10 ,  C07D413/12 ,  C07D413/04 ,  C07D417/06 ,  C07D413/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D417/04 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/22 ,  C07D211/44 ,  C07D211/46 ,  C07D211/78 ,  C07D211/88 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06 ,  C07D417/08 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

公开(公告)号：US20150266881A1

公开(公告)日：2015-09-24

申请号：US14435085

申请日：2013-10-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07D231/38 ,  C07C237/38 ,  C07C237/30 ,  C07D241/12 ,  C07D213/36 ,  C07D471/04 ,  C07D207/46 ,  C07D241/18 ,  C07D319/18 ,  C07D265/36 ,  C07D333/20 ,  C07D285/135 ,  C07D277/38 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D223/12 ,  C07D513/04 ,  C07C237/40

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物，可用作精神分裂症，阿尔茨海默病，帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物：其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1，R 2和R 3各自独立地为氢原子，任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合，与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合，与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。

公开(公告)号：US11713311B2

公开(公告)日：2023-08-01

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18

CPC classification number: C07D409/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):




wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09751885B2

公开(公告)日：2017-09-05

申请号：US14435085

申请日：2013-10-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07C255/58 ,  C07C255/60 ,  C07D231/40 ,  C07C317/40 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  A61K45/06 ,  C07D309/14 ,  C07D319/18 ,  C07D413/12 ,  C07D241/12 ,  C07D417/12 ,  C07D261/14 ,  C07D207/12 ,  C07D285/135 ,  C07D211/58 ,  C07D295/135 ,  C07D213/40 ,  C07D207/46 ,  C07D213/36 ,  C07D223/12 ,  C07D231/38 ,  C07D241/18 ,  C07D265/36 ,  C07D277/38 ,  C07D333/20 ,  C07D405/12 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09718814B2

公开(公告)日：2017-08-01

申请号：US15203522

申请日：2016-07-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D417/12 ,  C07D417/14 ,  C07D213/82 ,  C07D333/38 ,  C07D285/135 ,  C07D409/14 ,  C07D231/12 ,  C07D413/14 ,  C07D277/56 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D413/12 ,  C07D307/81

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US09487511B2

公开(公告)日：2016-11-08

申请号：US14682695

申请日：2015-04-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D333/40 ,  C07D333/38 ,  C07D407/12 ,  C07D409/12 ,  C07D417/14 ,  C07D417/12 ,  C07D307/79 ,  C07D213/82 ,  C07D413/14 ,  C07D231/14 ,  C07D285/08 ,  C07D285/135

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US10968213B2

公开(公告)日：2021-04-06

申请号：US16455359

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81 ,  A61P43/00 ,  A61P35/00 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  A61P25/14 ,  A61P25/08 ,  A61P25/00 ,  A61K31/343 ,  A61K31/421 ,  A61K31/433

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US10414761B2

公开(公告)日：2019-09-17

申请号：US15882386

申请日：2018-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81 ,  C07D285/135

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.